课题基金 / 基金详情

Institute of Human Virology Annual Meeting 2011-2016

Institute of Human Virology Annual Meeting 2011-2016
人类病毒学研究所2011-2016年年会
批准号:
8270443
负责人:
ROBERT C GALLO
金额:
$3.57万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-18 至 2016-08-31

项目摘要

项目成果

ROBERT C GALLO的其他基金

相似基金

相关文献

中文摘要
翻译
说明(由申请人提供):人类病毒学研究所年度国际会议于1970年代中期在国家癌症研究所开始,汇集了世界上最重要的艾滋病毒/艾滋病生物学专家,特别是在基础和疫苗科学以及新的治疗和预防方法方面的专家。本次会议的五个具体目标是:在选定的项目主题中传播最新的研究成果,批判性地评估新发现对未来研究方向的影响,为讨论当前和新出现的问题提供论坛,确定、支持和培养下一代艾滋病研究人员,增加少数民族妇女和其他传统上在科学领域代表性不足的个人的参与。2010年,我们扩大了对疫苗的重视,以了解最近的成功如何指导艾滋病毒疫苗研究和开发的新方向。专家们介绍了目前正在进行人体临床试验的疫苗免疫原、确定保护的免疫相关因素的努力、治疗性疫苗接种的应用以及使我们更接近有效预防艾滋病毒疾病的疫苗提供战略。我们讨论了致癌病毒和新的癌症疫苗。癌症正在成为艾滋病毒感染者死亡的主要原因;这些领域在科学和医学方面是联系在一起的。我们通过邀请专家讨论艾滋病毒/艾滋病对撒哈拉以南非洲的具体影响,强调了发展中国家的艾滋病毒/艾滋病问题。每次会议都有不同的观点和不同种族的参与者。通过在会议材料和网上发布所有演讲者和海报摘要,会议结果与更广泛的科学界共享。年会还通过一项严格执行的新闻政策得到进一步加强,该政策禁止媒体成员在未经主持人许可的情况下披露年会上呈现的任何信息。第13届年会定于2011年10月30日至11月2日在马里兰州巴尔的摩举行。我们预计有400名与会者,其中包括NIH的重要代表。海报将在马里兰大学校园中心展出,晚间活动旨在让参与者与现有合作者建立新的科学伙伴关系,并培养下一代艾滋病毒/艾滋病研究人员。该项目包括“快速射击”环节,鼓励年轻科学家展示他们的数据并接受深思熟虑的批评。奖学金计划为妇女、少数民族和其他代表性不足的群体提供了参与的机会,费用很少,甚至免费。
英文摘要
DESCRIPTION (provided by applicant): The Annual International Meeting of the Institute of Human Virology began at the National Cancer Institute in the mid-1970s and brings together the world's foremost experts on the biology of HIV/AIDS, particularly on basic and vaccine science and new treatment and prevention approaches. The five specific aims of this conference are to disseminate the most current research findings within the selected program topics, critically assess the impact of new findings on future directions for research, provide a forum for discussion of current and emerging issues, identify, support, and build the next generation AIDS researcher, and increase participation by women ethnic/racial minorities and other individuals traditionally underrepresented in science. In 2010 we expanded the emphasis on vaccines to learn how recent successes may guide new directions in HIV vaccine research and development. Experts described vaccine immunogens currently in human clinical trials, efforts to define immune correlates of protection, applications for therapeutic vaccination and vaccine delivery strategies that are bringing us closer to effective protection from HIV disease. We held discussions of cancer-causing viruses and new cancer vaccines. Cancer is emerging as the leading cause of death for persons with HIV; these fields are linked in terms of science and medicine. We highlighted HIV/AIDS in the developing world by inviting experts on the specific impacts of HIV/AIDS on sub-Saharan Africa. Each session is organized with divergent perspectives and ethnically diverse participants. Conference results are shared with the broader scientific community through publication of all speaker and poster abstracts both in meeting materials and online. The Meeting is further strengthened by a strictly enforced press policy that prohibits members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. The 13th Annual Meeting is scheduled for October 30 - November 2, 2011 in Baltimore, MD. We anticipate 400 participants, with significant NIH representation. Posters will be displayed at the University of Maryland Campus Center, with evening activities designed to engage participants with existing collaborators, build new scientific partnerships, and foster the next generation of HIV/AIDS researcher. The program includes "Rapid-Fire" sessions that encourage young scientists to present their data and receive thoughtful critique. The Scholarship Initiative offers women, minorities, and other typically under-represented populations with the opportunity to participate for very little or at no cost.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Durable Antibody Mediated Protection Against HIV
  • 批准号:
    9141189
  • 项目类别:
  • 资助金额:
    $321.54万
  • 财政年份:
    2016
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
Admin-Core A
  • 批准号:
    9141190
  • 项目类别:
  • 资助金额:
    $21.77万
  • 财政年份:
    2016
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
FLSC Combined with Tat Toxoid as an HIV Prophylactic Vaccine
  • 批准号:
    7854606
  • 项目类别:
  • 资助金额:
    $47.83万
  • 财政年份:
    2009
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
FLSC Combined with Tat Toxoid as an HIV Prophylactic Vaccine
  • 批准号:
    8134640
  • 项目类别:
  • 资助金额:
    $13.57万
  • 财政年份:
    2009
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
海外基金